These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17084751)

  • 1. ACE inhibitors and aortic rupture.
    Naina HV; Harris S
    Lancet; 2006 Nov; 368(9547):1572; author reply 1572. PubMed ID: 17084751
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
    Keidar S; Kaplan M; Pavlotzky E; Coleman R; Hayek T; Hamoud S; Aviram M
    Circulation; 2004 May; 109(18):2213-20. PubMed ID: 15123520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.
    Habashi JP; Doyle JJ; Holm TM; Aziz H; Schoenhoff F; Bedja D; Chen Y; Modiri AN; Judge DP; Dietz HC
    Science; 2011 Apr; 332(6027):361-5. PubMed ID: 21493863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
    Costantino S; Millozzi F; Scarlata S
    Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tumor suppressive effect].
    Takai S; Miyazaki M
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():512-7. PubMed ID: 16895220
    [No Abstract]   [Full Text] [Related]  

  • 7. [ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors].
    Berger D
    Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712087
    [No Abstract]   [Full Text] [Related]  

  • 8. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
    Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
    Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atenolol versus Losartan in Marfan's Syndrome.
    Mallat Z; Tedgui A
    N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683
    [No Abstract]   [Full Text] [Related]  

  • 10. Atenolol versus Losartan in Marfan's Syndrome.
    Treasure T; Pepper J; Mohiaddin R
    N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
    [No Abstract]   [Full Text] [Related]  

  • 11. Atenolol versus Losartan in Marfan's Syndrome.
    Ziganshin BA; Mukherjee SK; Elefteriades JA
    N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
    [No Abstract]   [Full Text] [Related]  

  • 12. Atenolol versus Losartan in Marfan's Syndrome.
    Lacro RV; Dietz HC; Mahony L
    N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
    [No Abstract]   [Full Text] [Related]  

  • 13. Of Marfan's syndrome, mice, and medications.
    Bowen JM; Connolly HM
    N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389
    [No Abstract]   [Full Text] [Related]  

  • 14. ACE inhibitors and angiotensin II receptor antagonists in Crohn's disease management.
    Hume GE; Radford-Smith GL
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):645-51. PubMed ID: 19072342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis.
    Li L; Yamani N; Al-Naimat S; Khurshid A; Usman MS
    Eur J Prev Cardiol; 2020 Sep; 27(13):1447-1450. PubMed ID: 31260329
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary prevention using losartan in type 1 diabetic patients significantly reduces retinopathy.
    Cardiovasc J Afr; 2009; 20(4):265. PubMed ID: 19701543
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with acute coronary syndrome].
    Iino K; Ito H
    Nihon Rinsho; 2006 Apr; 64(4):734-41. PubMed ID: 16613192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endothelium--'man of the match in the cardiovascular stakes'.
    Cardiovasc J S Afr; 2005; 16(2):131. PubMed ID: 15915285
    [No Abstract]   [Full Text] [Related]  

  • 19. Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al.
    O'Rourke MF; Adji A; Weber T
    Vasc Med; 2016 Feb; 21(1):70. PubMed ID: 26669325
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M; Tylicki L; Rutkowski P; Rutkowski B
    Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.